Plasma-Activated Medium Potentiates the Immunogenicity of Tumor Cell Lysates for Dendritic Cell-Based Cancer Vaccines

Sergej Tomić, Andjelija Petrović, Nevena Puač, Nikola Škoro, Marina Bekić, Zoran Petrović, Miodrag Čolić

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)
11 Downloads (Pure)

Abstract

Autologous dendritic cells (DCs)-based vaccines are considered quite promising for cancer immunotherapy due to their exquisite potential to induce tumor antigen-specific cytotoxic T cells. However, a lack of efficient protocols for inducing immunogenic tumor antigens limits the efficacy of DC-based cancer vaccines. Here, we found that a plasma-activated medium (PAM) induces
immunogenic cell death (ICD) in tumor cells but not in an immortalized L929 cell line or human peripheral blood mononuclear cells. PAM induced an accumulation of reactive oxygen species (ROS), autophagy, apoptosis, and necrosis in a concentration-dependent manner. The tumor lysates prepared after PAM treatment displayed increased immunogenicity in a model of human monocytederived DCs, compared to the lysates prepared by a standard freezing/thawing method. Mature DCs loaded with PAM lysates showed an increased maturation potential, as estimated by their increased expression of CD83, CD86, CD40, IL-12/IL-10 production, and attenuated PDL1 and ILT-4 expression, compared to the DCs treated with control tumor lysates. Moreover, in co-culture with allogeneic T cells, DCs loaded with PAM-lysates increased the proportion of cytotoxic IFN-γ+ granzyme A+ CD8+ T cells and IL-17A-producing T cells and preserved the Th1 response. In contrast, control tumor lysates-treated DCs increased the frequency of Th2 (CD4+IL-4+), CD4, and CD8 regulatory T cell subtypes, none of which was observed with DCs loaded with PAM-lysates. Cumulatively, these results suggest that the novel method for preparing immunogenic tumor lysates with PAM could be suitable for improved DC-based immunotherapy of cancer patients.
Original languageEnglish
Article number1626
Number of pages23
JournalCancers
Volume13
Issue number7
Early online date1 Apr 2021
DOIs
Publication statusPublished - 1 Apr 2021

Bibliographical note

Funding Information:
This research was funded by Ministry of Education, Science and Technological Development, grant numbers 451-03-68/2020-14/200019 and 451-03-68/2020-14/200024 and Serbian Academy of Sciences and Arts F31.

Publisher Copyright:
© 2021 by the authors.

Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.

Funding Information:
This research was funded by Ministry of Education, Science and Technological Development, grant numbers 451-03-68/2020-14/200019 and 451-03-68/2020-14/200024 and Serbian Academy of Sciences and Arts F31.

Publisher Copyright:
© 2021 by the authors.

Keywords

  • Dendritic cells
  • Plasma activated medium
  • Th polarization
  • Tumor vaccines
  • dendritic cells
  • tumor vaccines
  • plasma activated medium

Fingerprint

Dive into the research topics of 'Plasma-Activated Medium Potentiates the Immunogenicity of Tumor Cell Lysates for Dendritic Cell-Based Cancer Vaccines'. Together they form a unique fingerprint.

Cite this